司帕沙星治疗肺结核的临床研究

Effect of sparfloxacin in treating pulmonary tuberculosis

目的评价司帕沙星治疗肺结核的疗效。方法117例初治菌阳肺结核,随机分为治疗组(2HRSP/4HR、60例)和对照组(2HRZ/4HR、57例)进行短程化疗。结果治疗组和对照组2个月痰菌阴转率分别为95.0%和82.4%;满疗程痰菌阴转率分别为98.3%和98.0%。胸部X线所见,治疗组和对照组病灶吸收率分别为98.3%和96.5%,空洞闭合率两组分别为74.2%和51.6%。治疗组和对照组不良反应发生率分别为12.5%和9.8%。结论司帕沙星是一种新的、有效的、安全的抗结核药物。

Objective To assess antitubereulosis efficacy of spadloxacin. Methods 117 new smear positive pulmonary tuberculosis patients were randomly allocated into treatment group （60 cases, receiving 2HRZSP/4HR regimen） and Controls （57eases, 2HRZ/ 4HR）. Results The suptum negative conversion rates at two month in treatment group and the controls were 95.0% and 82. 4% resectivaly, and the end of chemotheraphy 98. 3% and 98. 0%. Chest radiography showed remarkable improvenend. Conclusion Sparfloxacin is a effective and safety medicine which can cure pULmonary tuberculosis.